Premium
Reversion from precore/core promoter mutants to wild‐type hepatitis B virus during the course of lamivudine therapy
Author(s) -
Cho Sung Won,
Hahm KiBaik,
Kim Jin Hong
Publication year - 2000
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1053/jhep.2000.19618
Subject(s) - lamivudine , hepatitis b virus , hbeag , virology , orthohepadnavirus , reversion , exacerbation , seroconversion , promoter , medicine , virus , hepadnaviridae , mutation , biology , gene , immunology , hbsag , genetics , gene expression , phenotype
The effect of lamivudine administration on the evolution of precore/core promoter mutation is unknown. The aim of this study was to determine the changes of precore/core promoter sequences in chronic type B hepatitis patients treated with lamivudine. Serial sera were obtained from 11 patients before, at the beginning of, and during therapy. Serum samples were polymerase chain reaction‐amplified, and nucleotide sequences of hepatitis B virus (HBV) were analyzed. At baseline, precore and core promoter mutations were found in 6 and 4 of 11 patients, respectively. A precore stop codon mutant was replaced by a wild‐type virus in all 6 patients infected with precore mutant at a median treatment of 12 months (vs. before therapy; P = .011). Mutations in the core promoter appeared in only 1 of 10 patients (vs. before therapy; P = .021). However, precore and core promoter mutations appeared in 5 and 7 of 10 patients at a median treatment of 21 months, respectively. Acute exacerbation occurred after lamivudine withdrawal in 2 patients who had hepatitis B e antigen (HBeAg) loss or seroconversion. The serum remained HBeAg‐negative throughout the study period, and each of 2 patients had precore wild‐type virus during acute exacerbation. HBV mutants with core gene deletions are not eliminated completely during prolonged therapy in 2 patients in whom the HBV genomes had core gene deletions at baseline. In conclusion, lamivudine therapy resulted in reversion from precore/core promoter mutants to wild‐type. However, mutations in the precore and core promoter region reappeared during prolonged therapy. HBeAg‐negative wild‐type precore hepatitis B virus could be selected after lamivudine withdrawal in patients who had HBeAg loss or seroconversion.